u/erez_yilmaz

This. Ordering from regional stock takes the entire question off the table, which is why it comes up in every one of these threads.

Daily dosing, so what does the exposure profile look like across the day?

a shoulder is not an impurity until you can resolve it

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

Not convinced. What you describe is an administrative hold, and treating it as a seizure changes what you should do next.

Correction: that is a request for information, not a seizure notice. Different document, different process, different deadline.

Storage conditions came back specific rather than generic when I asked. That told me somebody had actually done stability work.

This. Asking what reference standard was used separates a real analytical claim from a plausible-looking one.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

the scale cannot distinguish tissue types and never could

Compared two scans from different clinics and panicked over a difference that was inside the error margin.

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

Kept every document including the dull ones. When a process started, having the dates in order made it short.

Agreed, and it is why FGP printing the column and gradient on the certificate is genuinely useful rather than decorative.

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

lyophilised and stored cold is the default for a reason

old_account_2023 is right that a purity figure without a method is not comparable to one with a method.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Milligram comparisons across molecule classes are meaningless.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

research-use-only material is not approved for human use

Small fix — that is net peptide content, not purity. Both are on the certificate and they differ substantially here.

baseline choice is a decision, not a measurement

the column has a history and it shows in the peak shape

catalogue depth is not the same as catalogue quality

Yes. Lean mass change during weight loss is expected; the useful question is the proportion, not whether it happens.

A hold, a request for information and a seizure are distinct administrative events. Each has its own process and deadlines, and the notice itself states which one you have.

Yes — keep both the prescription and the receipt. Claims processes ask for both and never at a convenient moment.

Stocked lines and made-to-order lines have different lead times and different storage histories.

isabela_nilsen is right that a purity figure without a method is not comparable to one with a method.

Phase 2 or phase 3?

How many weeks between the two scans?

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

Research-use-only labelling is a description of intended use, not a customs classification. It does not by itself determine how anything is treated at a border.

Is that baseline drawn by the software or by hand?

Sent an unusual compound to VendorInvestigate because nobody on this site had ever posted one. 98.7% against a claimed 98.5%.

Agreed that thin testing here says something about the members, not about the material.

Storage guidance that names a temperature, a state and a duration reflects actual stability work. Generic guidance usually reflects a template.

you cannot report to two decimals off that baseline

the column has a history and it shows in the peak shape

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.